Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $47,353.80 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,335 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $20.28, for a total value of $47,353.80. Following the transaction, the insider now directly owns 169,144 shares in the company, valued at approximately $3,430,240.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Thursday, May 30th, Soleil Boughton sold 129,667 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.55, for a total value of $2,664,656.85.
• On Tuesday, May 28th, Soleil Boughton sold 2,502 shares of Hims & Hers Health stock. The stock was sold at an average price of $17.33, for a total value of $43,359.66.
• On Monday, May 20th, Soleil Boughton sold 4,915 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.01, for a total value of $98,349.15.
• On Monday, May 13th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $12.33, for a total value of $30,861.99.
• On Monday, April 29th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $12.56, for a total value of $31,437.68.
• On Monday, April 15th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $13.95, for a total value of $34,916.85.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $21.04 on Friday. The stock’s 50-day simple moving average is $19.10 and its two-hundred day simple moving average is $14.25. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $25.74.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The business had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.05) EPS. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on HIMS shares. TD Cowen boosted their target price on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday. Bank of America boosted their target price on Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. Piper Sandler boosted their target price on Hims & Hers Health from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Thursday. Seaport Res Ptn restated a “buy” rating on shares of Hims & Hers Health in a research note on Friday, April 26th. Finally, Canaccord Genuity Group started coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They set a “buy” rating and a $20.00 price objective on the stock. Seven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $18.36.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Hims & Hers Health by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after purchasing an additional 136,907 shares in the last quarter. Forerunner Ventures Management LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter worth about $86,836,000. Dimensional Fund Advisors LP boosted its holdings in shares of Hims & Hers Health by 9.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock worth $19,117,000 after purchasing an additional 193,507 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after purchasing an additional 1,634,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Hims & Hers Health by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,294,759 shares of the company’s stock worth $11,523,000 after purchasing an additional 22,009 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.